Scientists from the University of East Anglia (UEA) and Oxford BioDynamics have developed a blood test that accurately diagnoses Chronic Fatigue Syndrome (ME/CFS) with a reported accuracy of 96%. ME/CFS is a condition characterized by severe fatigue that persists despite rest, affecting millions worldwide, including over 400,000 in the UK. Historically, diagnosing this illness has been challenging, often leading to misdiagnosis or dismissal of symptoms.
The test's lead researcher, Professor Dmitry Pshezhetskiy, emphasized the significance of the breakthrough, noting that many patients have experienced skepticism regarding their condition in the absence of definitive diagnostic tools. The new blood test could facilitate earlier diagnoses and improve management strategies for those suffering from ME/CFS.
Utilizing Oxford BioDynamics' EpiSwitch® 3D Genomics technology, researchers analyzed blood samples from individuals with severe ME/CFS, comparing them to samples from healthy volunteers. This technology examines the three-dimensional folding of DNA within cells, which plays a crucial role in gene regulation. The study identified a unique genomic pattern present in ME/CFS patients but absent in healthy individuals.
In addition to diagnosing ME/CFS, researchers hope that this discovery may lead to similar diagnostic tests for long Covid, which presents a comparable cluster of symptoms. The findings suggest potential biological markers for future treatments, highlighting immune system involvement and inflammation pathways that may be targeted for therapeutic interventions.
As this research progresses, it could pave the way for more personalized care and effective treatment options for individuals diagnosed with ME/CFS. The study has been published in the Journal of Translational Medicine, marking a pivotal advancement in the understanding and management of this complex illness.